NASDAQ:CLSD Clearside Biomedical Q2 2024 Earnings Report $0.43 +0.01 (+2.79%) Closing price 04:00 PM EasternExtended Trading$0.42 -0.01 (-2.04%) As of 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Clearside Biomedical EPS ResultsActual EPS-$0.10Consensus EPS -$0.14Beat/MissBeat by +$0.04One Year Ago EPS-$0.15Clearside Biomedical Revenue ResultsActual Revenue$0.09 millionExpected Revenue$0.25 millionBeat/MissMissed by -$160.00 thousandYoY Revenue GrowthN/AClearside Biomedical Announcement DetailsQuarterQ2 2024Date8/12/2024TimeAfter Market ClosesConference Call DateMonday, August 12, 2024Conference Call Time4:00PM ETUpcoming EarningsClearside Biomedical's Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q2 2025 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Clearside Biomedical Earnings HeadlinesClearside Biomedical stock soars after Health Canada approves XIPEREJuly 25, 2025 | in.investing.comClearside Biomedical Receives Canadian Approval for XIPERE® to Treat Uveitic Macular Edema via Suprachoroidal DeliveryJuly 25, 2025 | msn.comHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.August 5 at 2:00 AM | The Oxford Club (Ad)Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in CanadaJuly 23, 2025 | globenewswire.comHC Wainwright & Co. Downgrades Clearside Biomedical (CLSD)July 20, 2025 | msn.comClearside Biomedical Insider Trading Activity | NASDAQ:CLSD | BenzingaJuly 18, 2025 | benzinga.comSee More Clearside Biomedical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Clearside Biomedical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Clearside Biomedical and other key companies, straight to your email. Email Address About Clearside BiomedicalClearside Biomedical (NASDAQ:CLSD), a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.View Clearside Biomedical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Palantir Stock Soars After Blowout Earnings ReportVertical Aerospace's New Deal and Earnings De-Risk ProductionAmazon's Earnings: What Comes Next and How to Play ItApple Stock: Big Earnings, Small Move—Time to Buy?Why Robinhood Just Added Upside Potential After a Q2 Earnings DipMicrosoft Blasts Past Earnings—What’s Next for MSFT?Visa Beats Q3 Earnings Expectations, So Why Did the Market Panic? Upcoming Earnings Airbnb (8/6/2025)AppLovin (8/6/2025)DoorDash (8/6/2025)Fortinet (8/6/2025)Brookfield Asset Management (8/6/2025)Cencora (8/6/2025)CRH (8/6/2025)Walt Disney (8/6/2025)Emerson Electric (8/6/2025)Energy Transfer (8/6/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.